Cargando…
Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725740/ https://www.ncbi.nlm.nih.gov/pubmed/23935640 http://dx.doi.org/10.1155/2013/724360 |
_version_ | 1782278580372242432 |
---|---|
author | Hamad, Ahmad Sahli, Zeyad El Sabban, Maya Mouteirik, Maha Nasr, Rihab |
author_facet | Hamad, Ahmad Sahli, Zeyad El Sabban, Maya Mouteirik, Maha Nasr, Rihab |
author_sort | Hamad, Ahmad |
collection | PubMed |
description | Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML. |
format | Online Article Text |
id | pubmed-3725740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37257402013-08-09 Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells Hamad, Ahmad Sahli, Zeyad El Sabban, Maya Mouteirik, Maha Nasr, Rihab Stem Cells Int Review Article Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML. Hindawi Publishing Corporation 2013 2013-07-09 /pmc/articles/PMC3725740/ /pubmed/23935640 http://dx.doi.org/10.1155/2013/724360 Text en Copyright © 2013 Ahmad Hamad et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Hamad, Ahmad Sahli, Zeyad El Sabban, Maya Mouteirik, Maha Nasr, Rihab Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title_full | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title_fullStr | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title_full_unstemmed | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title_short | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
title_sort | emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725740/ https://www.ncbi.nlm.nih.gov/pubmed/23935640 http://dx.doi.org/10.1155/2013/724360 |
work_keys_str_mv | AT hamadahmad emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT sahlizeyad emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT elsabbanmaya emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT mouteirikmaha emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT nasrrihab emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells |